SEH1L and type 1 diabetes mellitus: They also raise the possibility that generating or repurposing FDA-approved drugs that inhibit sEH1 (TPPU), downregulate So1P (FTY720), interrupt LT and HETE signaling (receptor antagonists), or mimic the effects of PGE1 (Alprostadil) and SPMs (resolvins) could be beneficial in altering the course of T1D onset and/or progression.